Education
About Us
Working with TipRanks
Follow Us
Vicarious Surgical (RBOT)
NYSE:RBOT
RBOT Stock Chart & Stats
$4.37
-$0.68(-4.53%)
At close: 4:00 PM EST
$4.37
-$0.68(-4.53%)
Day’s Range― - ―
52-Week Range$4.23 - $19.00
Previous CloseN/A
Volume30.88K
Average Volume (3M)90.39K
Market Cap
$30.45M
Enterprise Value$33.77M
Total Cash (Recent Filing)$23.96M
Total Debt (Recent Filing)$13.20M
Price to Earnings (P/E)―
Beta2.38
Next Earnings
Nov 13, 2025EPS Estimate
-2.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.23
Shares Outstanding5,894,024
10 Day Avg. Volume138,739
30 Day Avg. Volume90,387
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)1.66
Price to Sales (P/S)0.00
P/FCF Ratio-1.54
Enterprise Value/Market Cap1.11
Enterprise Value/Revenue16.16
Enterprise Value/Gross Profit-138.41
Enterprise Value/Ebitda-0.57
Forecast
1Y Price Target
$10.00Price Target Upside128.83% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
LeadershipA new CEO with over 20 years of leadership in the healthcare and financial industry has been appointed, bringing valuable experience to lead the company through its current development and clinical programs.
Leadership ChangeThe leadership change was deemed necessary at a pivotal stage for the company, suggesting positive expectations from the new CEO's approach.
Strategic VisionThe strategic vision focuses on completing a fully integrated, production-equivalent system and initiating full system verification and validation, which is considered the best use of company resources.
Bears Say
Capital ChallengeRBOT's capital position remains its biggest challenge as RBOT exited 2Q25 with ~$24.0M in cash and continues to expect ~$50M in cash burn for FY25 forcing RBOT to make some tough decisions.
Financing NeedsRBOT will need to either reduce cash burn substantially or find sources of financing potentially requiring a complete recapitalization of the company.
Product Development DelayThe company will hold off on its clinical trial initiation in order to further develop its system to be 'product ready', indicating a pause until further notice.
Vicarious Surgical News
RBOT FAQ
What was Vicarious Surgical’s price range in the past 12 months?
Vicarious Surgical lowest stock price was $4.23 and its highest was $19.00 in the past 12 months.
What is Vicarious Surgical’s market cap?
Vicarious Surgical’s market cap is $30.45M.
When is Vicarious Surgical’s upcoming earnings report date?
Vicarious Surgical’s upcoming earnings report date is Nov 13, 2025 which is in 2 days.
How were Vicarious Surgical’s earnings last quarter?
Vicarious Surgical released its earnings results on Aug 12, 2025. The company reported -$2.23 earnings per share for the quarter, beating the consensus estimate of -$2.497 by $0.267.
Is Vicarious Surgical overvalued?
According to Wall Street analysts Vicarious Surgical’s price is currently Undervalued.
Does Vicarious Surgical pay dividends?
Vicarious Surgical does not currently pay dividends.
What is Vicarious Surgical’s EPS estimate?
Vicarious Surgical’s EPS estimate is -2.33.
How many shares outstanding does Vicarious Surgical have?
Vicarious Surgical has 5,894,024 shares outstanding.
What happened to Vicarious Surgical’s price movement after its last earnings report?
Vicarious Surgical reported an EPS of -$2.23 in its last earnings report, beating expectations of -$2.497. Following the earnings report the stock price went down -24.348%.
Which hedge fund is a major shareholder of Vicarious Surgical?
Currently, no hedge funds are holding shares in RBOT
Company Description
Vicarious Surgical
Vicarious Surgical Inc. engages in developing and selling single-incision surgical robot that virtually transports surgeons inside the patient to perform minimally invasive surgery. It offers Vicarious System, a single-incision surgical robot for ventral hernia repair. The company was incorporated in 2014 and is headquartered in Waltham, Massachusetts.
RBOT Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects a company undergoing significant leadership transition and strategic reassessment. While there are positives in the form of reduced operating expenses and net loss, major challenges remain, particularly around delays in clinical trials and resource constraints. The uncertainty in achieving future milestones further complicates the outlook.View all RBOT earnings summariesRBOT Stock 12 Month Forecast
Average Price Target
$10.00
▲(128.83% Upside)
Technical Analysis
LivaNova
―
Xtant Medical Holdings
―
Inspire Medical Systems
―
Outset Medical
―
PROCEPT BioRobotics
―
Ownership Overview
13.07% Insiders
3.49% Mutual Funds
<0.01% Other Institutional Investors
80.75% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---